Liraglutide, a glucagon‑like peptide‑1 analog, inhibits high glucose‑induced oxidative stress and apoptosis in neonatal rat cardiomyocytes

Zhang,Lihui; Li,Caige; Zhu,Qiuxiao; Li,Na; Zhou,Hong

doi:10.3892/etm.2019.7388

Liraglutide, a glucagon‑like peptide‑1 analog, inhibits high glucose‑induced oxidative stress and apoptosis in neonatal rat cardiomyocytes

Authors:
- Lihui Zhang
- Caige Li
- Qiuxiao Zhu
- Na Li
- Hong Zhou
View Affiliations

Affiliations: Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: March 13, 2019 https://doi.org/10.3892/etm.2019.7388
Pages: 3734-3740

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiomyocyte apoptosis serves an important role in diabetic cardiomyopathy. Liraglutide, a glucagon‑like peptide‑1 analog, has been indicated to exert a cardioprotective effect. However, the role of liraglutide on cardiomyocyte apoptosis in hyperglycemia is not fully understood. The aim of the current study was to assess whether liraglutide protects against high glucose (HG)‑induced cardiomyocyte apoptosis in vitro. Sprague‑Dawley neonatal rat cardiomyocytes were cultured in Dulbecco's modiﬁed Eagle's medium, supplemented with 5.5 or 25 mmol/l D‑glucose or 5.5 mmol/l D‑glucose + 19.5 mmol/l mannitol, in the presence or absence of liraglutide (10 or 100 nmol/l). Cell viability was assessed via an MTT assay and early apoptosis rates were assessed via flow cytometry. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) content in cell supernatants were measured. Bcl‑2 associated X (Bax), B‑cell lymphoma‑2 (Bcl‑2) and cleaved/full caspase‑3 protein levels were determined via western blotting. The results revealed that liraglutide effectively inhibited the HG‑induced increase in early apoptosis and MDA content and markedly increased SOD activity. Furthermore, liraglutide markedly inhibited the HG‑induced increase in Bax and cleaved caspase‑3 protein expression, and upregulated the expression of Bcl‑2. The present study demonstrated that liraglutide suppressed HG‑induced oxidative stress and cardiomyocyte apoptosis. Thus, the anti‑apoptotic actions of liraglutide may be attributable, in part, to the inhibition of Bax, the inhibition of caspase‑3 activation and the upregualtion of Bcl‑2.

View Figures

View References

1	Jia G, Whaley-Connell A and Sowers JR: Diabetic cardiomyopathy: A hyperglycaemia-and insulin-resistance-induced heart disease. Diabetologia. 61:21–28. 2018. View Article : Google Scholar : PubMed/NCBI
2	Aneja A, Tang WH, Bansilal S, Garcia MJ and Farkouh ME: Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 121:748–757. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y, Tan Y, Cui W, Liu B, Cui T, et al: Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: Roles of Nrf2 and NF-κB. Am J Physiol Heart Circ Physiol. 304:H567–H578. 2013. View Article : Google Scholar : PubMed/NCBI
4	Guan SJ, Ma ZH, Wu YL, Zhang JP, Liang F, Weiss JW, Guo QY, Wang JY, Ji ES and Chu L: Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats. Food Chem Toxicol. 50:1874–1882. 2012. View Article : Google Scholar : PubMed/NCBI
5	Scheen AJ: Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 122:1439–1459. 2018. View Article : Google Scholar : PubMed/NCBI
6	Drucker DJ: The biology of incretin hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
7	Drucker DJ, Habener JF and Holst JJ: Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 127:4217–4227. 2017. View Article : Google Scholar : PubMed/NCBI
8	Drucker DJ: The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24:15–30. 2016. View Article : Google Scholar : PubMed/NCBI
9	Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M and Drucker DJ: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 58:975–983. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N and McDonagh PF: Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 43:300–305. 2011. View Article : Google Scholar : PubMed/NCBI
11	Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 375:311–322. 2016. View Article : Google Scholar : PubMed/NCBI
12	Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 375:1834–1844. 2016. View Article : Google Scholar : PubMed/NCBI
13	Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M and Drucker DJ: Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 136:849–870. 2017. View Article : Google Scholar : PubMed/NCBI
14	Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, Marino Gammazza A, Barbagallo I, Isenovic ER, Banach M, et al: Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study. J Clin Endocrinol Metab. 100:603–606. 2015. View Article : Google Scholar : PubMed/NCBI
15	Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, et al: Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study. Cardiovasc Diabetol. 15:1622016. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Liu Y, Chen L, Wang Y and Li J: Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J Diabetes Res. 2013:6305372013. View Article : Google Scholar : PubMed/NCBI
17	Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D and Takayanagi R: GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis. 240:250–259. 2015. View Article : Google Scholar : PubMed/NCBI
18	Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ and Husain M: A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 127:74–85. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liu C, Xue R, Wu D, Wu L, Chen C, Tan W, Chen Y and Dong Y: REDD1 attenuates cardiac hypertrophy via enhancing autophagy. Biochem Biophys Res Commun. 454:215–220. 2014. View Article : Google Scholar : PubMed/NCBI
20	Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G and Perticone F: Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrin. 57:464–473. 2017. View Article : Google Scholar
21	Okada K, Kotani K, Yaqyu H, Ando A, Osuqa J and Ishibashi S: Effects of treatment with liraglutide on oxidative strss and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine. 47:962–964. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dai Y, Mehta JL and Chen M: Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 27:371–380. 2013. View Article : Google Scholar : PubMed/NCBI
23	Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB and Basu A: The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res. 11:419–430. 2014. View Article : Google Scholar : PubMed/NCBI
24	Guo S, Yao Q, Ke Z, Chen H, Wu J and Liu C: Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK. Mol Cell Endocrinol. 412:85–94. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zhang F, Lin X, Yu L, Li W, Qian D, Cheng P, He L, Yang H and Zhang C: Low-dose radiation prevents type 1 diabetes-induced cardiomyopathy via activation of AKT mediated anti-apoptotic and anti-oxidant effects. J Cell Mol Med. 20:1352–1366. 2016. View Article : Google Scholar : PubMed/NCBI
26	Despa S, Margulies KB, Chen L, Knowlton AA, Havel PJ, Taegtmeyer H, Bers DM and Despa F: Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: A study in humans and rats. Circ Res. 110:598–608. 2012. View Article : Google Scholar : PubMed/NCBI
27	Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T and Murohara T: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol. 305:H295–H304. 2013. View Article : Google Scholar : PubMed/NCBI
28	Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, et al: Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 62:1697–1708. 2013. View Article : Google Scholar : PubMed/NCBI
29	XiaoTian L, QiNan W, XiaGuang G, WuQuan D, Bing C and ZiWen L: Exenatide activates the APPL1-AMPK-PPARα axis to prevent diabetic cardiomyocyte apoptosis. J Diabetes Res. 2016:42197352016. View Article : Google Scholar : PubMed/NCBI
30	Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA and Drucker DJ: GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 19:567–575. 2013. View Article : Google Scholar : PubMed/NCBI
31	Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM and Reimann F: Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes. 63:1224–1233. 2014. View Article : Google Scholar : PubMed/NCBI
32	Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ and Drucker DJ: Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 3:507–517. 2014. View Article : Google Scholar : PubMed/NCBI
33	Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ and Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI
34	Younce CW, Burmeister MA and Ayala JE: Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol. 304:C508–C518. 2013. View Article : Google Scholar : PubMed/NCBI
35	Liu H, Chen X, Han Y, Li C, Chen P, Su S, Zhang Y and Pan Z: Rho kinase inhibition by fasudil suppresses lipopolysaccharide-induced apoptosis of rat pulmonary microvascular endothelial cells via JNK and p38 MAPK pathway. Biomed Pharmacother. 68:267–275. 2014. View Article : Google Scholar : PubMed/NCBI
36	Gao H, Hou F, Dong R, Wang Z, Zhao C, Tang W and Wu Y: Rho-Kinase inhibitor fasudil suppresses high glucose-induced H9c2 cell apoptosis through activation of autophagy. Cardiovasc Ther. 34:352–359. 2016. View Article : Google Scholar : PubMed/NCBI